



## VULNERABLE PATIENT ACCESS TO NEW COVID TREATMENTS

Sheffield LMC has received a number of enquiries about vulnerable patient access to new COVID treatments Sortrivismab (IV monoclonal antibody) and Molnupiravir (oral antiviral).

Many patients will have already been identified centrally by NHSX and received a letter and personal PCR testing kit for if and when they have symptoms suggestive of COVID. Some patients may have been diagnosed more recently with an “at-risk” condition and not have received central notification.

If a patient has COVID and you think they may be eligible for these treatments you can refer via eRS to the COVID Medicines Delivery Unit or via email: [sth.cمدu@nhs.net](mailto:sth.cمدu@nhs.net) with the patient’s:

- name
- date of birth
- NHS number
- phone number
- date of onset of symptoms
- date of positive PCR result
- details of why you think the patient may reasonably fit the criteria for treatment.

The team at the Infectious Diseases Unit at the Royal Hallamshire Hospital (RHH) will then contact the patient to assess whether treatment is required.

IV Sortrivismab is preferred as it has greater efficacy at preventing serious disease. Patients will have to attend RHH for this. If oral treatment with Molnupiravir is required, this will be issued from a hospital supply and either collected by a non-infected relative or delivered to the housebound patient.

Treatment will not involve general practice or local pharmacies.

The conditions that put patients at most risk and, therefore, most likely to benefit from these treatments can be found in the appendices of the guidance available [here](#).